Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Maridebart Cafraglutide (AMG 133) in Overweight or Obesity
NCT07313761Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maridebart cafraglutide in obesity (2 arms), sponsored by Amgen. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity, Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration and 1 more. Started Dec 2025; status: completed.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07313761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07313761.